Works matching IS 01676997 AND DT 2017 AND VI 35 AND IP 6

Results: 20

Human mass balance study and metabolite profiling of C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 751, doi. 10.1007/s10637-017-0451-2

By:

van Andel, Lotte;
Zhang, Z.;
Lu, S.;
Kansra, V.;
Agarwal, S.;
Hughes, L.;
Tibben, M.;
Gebretensae, A.;
Lucas, L.;
Hillebrand, M.;
Rosing, H.;
Schellens, J.;
Beijnen, J.

Publication type:

Article

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 766, doi. 10.1007/s10637-017-0454-z

By:

Stathis, A.;
Hess, D.;
Moos, R.;
Homicsko, K.;
Griguolo, G.;
Joerger, M.;
Mark, M.;
Ackermann, C.;
Allegrini, S.;
Catapano, C.;
Xyrafas, A.;
Enoiu, M.;
Berardi, S.;
Gargiulo, P.;
Sessa, C.

Publication type:

Article

A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 773, doi. 10.1007/s10637-017-0460-1

By:

Kim, Gun;
Reid, Tony;
Shin, Sang;
Rha, Sun;
Ahn, Joong;
Lee, Sung;
Chung, Hyun

Publication type:

Article

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 782, doi. 10.1007/s10637-017-0463-y

By:

Lee, Su;
Lee, Seon;
Lee, Weon;
Yoo, Jin;
Sun, Jong-Mu;
Lee, Jeeyun;
Park, Se;
Park, Joon;
Ahn, Myung-Ju;
Lim, Ho;
Kang, Won;
Park, Young

Publication type:

Article

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab.

Published in:

2017

By:

Mamesaya, Nobuaki;
Kenmotsu, Hirotsugu;
Takahashi, Toshiaki

Publication type:

Report

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 842, doi. 10.1007/s10637-017-0476-6

By:

Heidelberger, Valentine;
Goldwasser, François;
Kramkimel, Nora;
Jouinot, Anne;
Franck, Nathalie;
Arrondeau, Jennifer;
Guégan, Sarah;
Mansuet-Lupo, Audrey;
Alexandre, Jérôme;
Damotte, Diane;
Avril, Marie-Françoise;
Dupin, Nicolas;
Aractingi, Sélim

Publication type:

Article

Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 848, doi. 10.1007/s10637-017-0481-9

By:

Takenaka, Tomoyoshi;
Yamazaki, Koji;
Miura, Naoko;
Harada, Naohiko;
Takeo, Sadanori

Publication type:

Article

Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 671, doi. 10.1007/s10637-017-0483-7

By:

Liberal, Joana;
Carmo, Anália;
Gomes, Célia;
Cruz, Maria;
Batista, Maria

Publication type:

Article

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 791, doi. 10.1007/s10637-017-0486-4

By:

Watanabe, Junichiro;
Ito, Yoshinori;
Ohsumi, Shozo;
Mizutani, Mitsuhiro;
Tashiro, Hideya;
Sakurai, Kenichi;
Takahashi, Masato;
Saito, Tsuyoshi;
Tsurutani, Junji;
Mukai, Hirofumi;
Yoshinami, Tetsuhiro;
Takao, Shintaro;
Yamamoto, Yasuhisa;
Matsuoka, Toshiyuki;
Iwase, Hirotaka;
Iwata, Hiroji;
Nakamura, Seigo;
Saeki, Toshiaki

Publication type:

Article

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 682, doi. 10.1007/s10637-017-0488-2

By:

Wehbe, Mohamed;
Lo, Cody;
Leung, Ada;
Dragowska, Wieslawa;
Ryan, Gemma;
Bally, Marcel

Publication type:

Article

Synthesis, characterization, and evaluation of Cd[L-proline], a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 691, doi. 10.1007/s10637-017-0489-1

By:

Chidambaram, Anusha;
Sekar, Arunachalam;
S.H., Kavya;
Chidambaram, Ramesh;
Arunachalam, Kalaiarasi;
G.P., Senthilkumar;
Vilwanathan, Ravikumar

Publication type:

Article

Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 706, doi. 10.1007/s10637-017-0493-5

By:

Chan, Ariane;
Gilfillan, Connie;
Templeton, Nikki;
Paterson, Ian;
Northcote, Peter;
Miller, John

Publication type:

Article

Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 718, doi. 10.1007/s10637-017-0494-4

By:

Dragoj, Miodrag;
Bankovic, Jasna;
Sereti, Evangelia;
Stojanov, Sofija;
Dimas, Konstantinos;
Pesic, Milica;
Stankovic, Tijana

Publication type:

Article

Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 733, doi. 10.1007/s10637-017-0496-2

By:

Lee, Hyo;
Kim, Bo-Kyoung;
Yoon, Kyoung;
Kim, Yong-Chul;
Han, Sun-Young

Publication type:

Article

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 800, doi. 10.1007/s10637-017-0504-6

By:

Hasegawa, Kosei;
Kagabu, Masahiro;
Mizuno, Mika;
Oda, Katsutoshi;
Aoki, Daisuke;
Mabuchi, Seiji;
Kamiura, Shoji;
Yamaguchi, Satoshi;
Aoki, Yoichi;
Saito, Toshiaki;
Yunokawa, Mayu;
Takehara, Kazuhiro;
Okamoto, Aikou;
Ochiai, Kazunori;
Kimura, Tadashi

Publication type:

Article

Mechanisms of cancer cell killing by sea cucumber-derived compounds.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 820, doi. 10.1007/s10637-017-0505-5

By:

Wargasetia, Teresa;
Widodo

Publication type:

Article

Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 827, doi. 10.1007/s10637-017-0510-8

By:

Shepshelovich, D.;
Goldvaser, H.;
Wang, L.;
Abdul Razak, A.;
Bedard, P.

Publication type:

Article

Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 813, doi. 10.1007/s10637-017-0511-7

By:

Parikh, Anish;
Kozuch, Peter;
Rohs, Nicholas;
Becker, Daniel;
Levy, Benjamin

Publication type:

Article

Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 834, doi. 10.1007/s10637-017-0512-6

By:

Cao, Meihui;
Li, Feifei;
Wang, Yue;
Zhang, Jingdong

Publication type:

Article

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Published in:

Investigational New Drugs, 2017, v. 35, n. 6, p. 742, doi. 10.1007/s10637-017-0445-0

By:

Smyth, Lillian;
Monson, Kelsey;
Jhaveri, Komal;
Drilon, Alexander;
Li, Bob;
Abida, Wassim;
Iyer, Gopa;
Gerecitano, John;
Gounder, Mrinal;
Harding, James;
Voss, Martin;
Makker, Vicky;
Ho, Alan;
Razavi, Pedram;
Iasonos, Alexia;
Bialer, Philip;
Lacouture, Mario;
Teitcher, Jerrold;
Erinjeri, Joseph;
Katabi, Nora

Publication type:

Article